Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

Statistical Methods for Rates and Proportions

2003 • 17,930 citations

Gene expression profiling predicts clinical outcome of breast cancer

2002 • 9,314 citations

Statistical Methods for Rates and Proportions.

1981 • 8,945 citations

pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

1991 • 5,979 citations

Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

1984 • 4,180 citations

DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS

1989 • 1,799 citations

Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry

2000 • 690 citations

erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer

1998 • 667 citations

erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

1998 • 628 citations

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.

1995 • 422 citations

Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer

2000 • 388 citations

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

2001 • 328 citations

When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer

2001 • 302 citations

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

2003 • 292 citations

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

1993 • 271 citations

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

2002 • 250 citations

Inflammatory Breast Cancer

1993 • 232 citations

Human DNA topoisomerase I: relaxation, roles, and damage control

2005 • 220 citations

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi

1996 • 196 citations

Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.

1997 • 174 citations

Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.

2002 • 174 citations

Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer

1997 • 136 citations

Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy

2002 • 120 citations

Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

2000 • 114 citations

Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy

2003 • 113 citations

Prediction of response to primary chemotherapy for operable breast cancer

1999 • 111 citations

HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

2001 • 106 citations

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer

2003 • 80 citations

Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.

2001 • 74 citations

Comparison of HER2/neuStatus Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry

2001 • 67 citations

Correlation between HER‐2 expression and response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma

2003 • 66 citations

c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy

1999 • 64 citations

Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy

2003 • 54 citations

Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer

1999 • 53 citations

ERBB2 overexpression in breast carcinomas

2000 • 51 citations

HER2

2000 • 51 citations

Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates

1993 • 49 citations

Human DNA-Topoisomerases – Diagnostic and Therapeutic Implications for Cancer

2000 • 43 citations

C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer.

1998 • 31 citations

Human DNA topoisomerase II-alpha

1997 • 12 citations